Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetaPHER: Herceptin SC + Perjeta + Docetaxel in HER2+ Advanced Breast Cancer
NCT02402712Phase 3Completed
- Sponsor
- Roche
- Start
- May 2015
- Primary completion
- Feb 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of trastuzumab in HER2-positive breast cancer, sponsored by Roche. Primary endpoints: Incidence of adverse events up to 24 months, Incidence and severity of adverse events Grade >= 3 up to 24 months and 1 more. Started May 2015; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02402712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402712.